This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Brofaromine
Accession Number
DB13876
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Consonar
Categories
UNII
6WV4B8Q07H
CAS number
63638-91-5
Weight
Average: 310.191
Monoisotopic: 309.036442
Chemical Formula
C14H16BrNO2
InChI Key
WZXHSWVDAYOFPE-UHFFFAOYSA-N
InChI
InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3
IUPAC Name
4-(7-bromo-5-methoxy-1-benzofuran-2-yl)piperidine
SMILES
COC1=CC2=C(OC(=C2)C2CCNCC2)C(Br)=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAmine oxidase [flavin-containing] A
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Brofaromine.Experimental, Illicit
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Brofaromine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Brofaromine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Brofaromine.Experimental
AcarboseBrofaromine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololBrofaromine may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Brofaromine.Experimental
AlbiglutideBrofaromine may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Brofaromine.Approved, Illicit
AliskirenBrofaromine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Brofaromine.Approved, Investigational
AlogliptinBrofaromine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Brofaromine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Brofaromine.Illicit
AlprenololBrofaromine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Brofaromine.Approved
AmbrisentanBrofaromine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineBrofaromine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineBrofaromine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineBrofaromine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Brofaromine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Brofaromine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Arformoterol.Approved, Investigational
AtenololBrofaromine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineBrofaromine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineBrofaromine may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Bambuterol.Approved
BenazeprilBrofaromine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideBrofaromine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBrofaromine may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Brofaromine.Approved, Illicit
BepridilBrofaromine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Brofaromine.Approved
BetaxololBrofaromine may increase the hypotensive activities of Betaxolol.Approved
BethanidineBrofaromine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Brofaromine is combined with Bezafibrate.Approved
BietaserpineBrofaromine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostBrofaromine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBrofaromine may increase the hypotensive activities of Bisoprolol.Approved
BosentanBrofaromine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Brofaromine may increase the hypotensive activities of BQ-123.Investigational
BretyliumBrofaromine may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Brimonidine.Approved
BromocriptineBrofaromine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololBrofaromine may increase the hypotensive activities of Bupranolol.Approved
BupropionBrofaromine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Brofaromine.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brofaromine.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Brofaromine.Approved
CadralazineBrofaromine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineBrofaromine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinBrofaromine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanBrofaromine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilBrofaromine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilBrofaromine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brofaromine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Brofaromine.Illicit, Vet Approved
CaroxazoneBrofaromine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololBrofaromine may increase the hypotensive activities of Carteolol.Approved
CarvedilolBrofaromine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololBrofaromine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideBrofaromine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Brofaromine.Illicit, Withdrawn
ChlorpropamideBrofaromine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneBrofaromine may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineBrofaromine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilBrofaromine may increase the hypotensive activities of Cilazapril.Approved
CirazolineBrofaromine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Brofaromine.Approved
ClemastineBrofaromine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Clenbuterol.Approved, Vet Approved
ClomipramineBrofaromine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineBrofaromine may increase the hypotensive activities of Clonidine.Approved
CloranololBrofaromine may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Brofaromine.Approved, Illicit
CryptenamineBrofaromine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Brofaromine.Approved
CyclopenthiazideBrofaromine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideBrofaromine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineBrofaromine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinBrofaromine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Brofaromine.Investigational
DebrisoquinBrofaromine may increase the hypotensive activities of Debrisoquin.Approved
DelaprilBrofaromine may increase the hypotensive activities of Delapril.Experimental
DeserpidineBrofaromine may increase the hypotensive activities of Deserpidine.Approved
DesipramineBrofaromine may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brofaromine.Approved
DexmethylphenidateBrofaromine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Brofaromine.Approved, Illicit
DextromethorphanBrofaromine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brofaromine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brofaromine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Brofaromine.Approved
DiazoxideBrofaromine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinBrofaromine may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermineBrofaromine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionBrofaromine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineBrofaromine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brofaromine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Brofaromine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brofaromine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brofaromine.Experimental, Illicit
DiltiazemBrofaromine may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brofaromine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Brofaromine is combined with Dipivefrin.Approved
DisopyramideBrofaromine may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Brofaromine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideBrofaromine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinBrofaromine may increase the serotonergic activities of Dosulepin.Approved
DoxapramBrofaromine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinBrofaromine may increase the hypotensive activities of Doxazosin.Approved
DoxepinBrofaromine may increase the serotonergic activities of Doxepin.Approved
DoxylamineBrofaromine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Brofaromine.Investigational
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Brofaromine.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Brofaromine is combined with Droxidopa.Approved, Investigational
DulaglutideBrofaromine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Brofaromine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Brofaromine.Experimental, Illicit
EfonidipineBrofaromine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Brofaromine.Approved, Investigational
EmpagliflozinBrofaromine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilBrofaromine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBrofaromine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineBrofaromine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Brofaromine.Approved, Investigational
EpanololBrofaromine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Brofaromine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpoprostenolBrofaromine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBrofaromine may increase the hypotensive activities of Eprosartan.Approved
ErgotamineBrofaromine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Brofaromine.Approved, Investigational
EsmirtazapineBrofaromine may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Brofaromine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brofaromine.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Brofaromine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brofaromine.Illicit, Vet Approved
ExenatideBrofaromine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineBrofaromine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamBrofaromine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brofaromine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidBrofaromine may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Brofaromine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Brofaromine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Formoterol.Approved, Investigational
FosinoprilBrofaromine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Brofaromine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Brofaromine.Approved, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Brofaromine.Experimental
GliclazideBrofaromine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBrofaromine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBrofaromine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideBrofaromine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzBrofaromine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelBrofaromine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineBrofaromine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineBrofaromine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineBrofaromine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorBrofaromine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBrofaromine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBrofaromine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypertensive activities of Brofaromine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Brofaromine.Approved, Illicit
HexamethoniumBrofaromine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineBrofaromine may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineBrofaromine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBrofaromine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBrofaromine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Brofaromine.Approved
ImidaprilBrofaromine may increase the hypotensive activities of Imidapril.Investigational
ImipramineBrofaromine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Brofaromine.Investigational, Withdrawn
IndapamideBrofaromine may increase the hypotensive activities of Indapamide.Approved
IndenololBrofaromine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminBrofaromine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartBrofaromine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirBrofaromine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineBrofaromine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineBrofaromine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanBrofaromine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproBrofaromine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Brofaromine.Approved
IprindoleBrofaromine may increase the serotonergic activities of Iprindole.Experimental
IproclozideBrofaromine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Brofaromine.Withdrawn
IrbesartanBrofaromine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Brofaromine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Brofaromine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Isoprenaline.Approved
IsradipineBrofaromine may increase the hypotensive activities of Isradipine.Approved
KetanserinBrofaromine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brofaromine.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Brofaromine.Approved, Nutraceutical, Withdrawn
LabetalolBrofaromine may increase the hypotensive activities of Labetalol.Approved
LacidipineBrofaromine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostBrofaromine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineBrofaromine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Brofaromine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brofaromine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Brofaromine.Approved
LevonordefrinBrofaromine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brofaromine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Brofaromine is combined with Linezolid.Approved, Investigational
LinsidomineBrofaromine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideBrofaromine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Brofaromine.Approved, Investigational
LisinoprilBrofaromine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Brofaromine.Approved
LithiumThe risk or severity of adverse effects can be increased when Brofaromine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Brofaromine.Illicit
LofepramineBrofaromine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineBrofaromine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanBrofaromine may increase the hypotensive activities of Losartan.Approved
MacitentanBrofaromine may increase the hypotensive activities of Macitentan.Approved
ManidipineBrofaromine may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brofaromine.Approved
MebanazineBrofaromine may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineBrofaromine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminBrofaromine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Brofaromine.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Brofaromine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Brofaromine.Experimental
MequitazineBrofaromine may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolBrofaromine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminBrofaromine may increase the hypoglycemic activities of Metformin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Brofaromine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Brofaromine.Approved, Illicit
MethoserpidineBrofaromine may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineBrofaromine may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Brofaromine.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Brofaromine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Brofaromine.Experimental
Methylene blueBrofaromine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateBrofaromine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololBrofaromine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneBrofaromine may increase the hypotensive activities of Metolazone.Approved
MetoprololBrofaromine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineBrofaromine may increase the hypotensive activities of Metyrosine.Approved
MianserinBrofaromine may increase the neurotoxic activities of Mianserin.Approved
MibefradilBrofaromine may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineBrofaromine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxymethamphetamine is combined with Brofaromine.Experimental, Illicit
MifepristoneBrofaromine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolBrofaromine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Brofaromine.Approved
MinaprineMinaprine may increase the hypertensive activities of Brofaromine.Approved
MinoxidilBrofaromine may increase the hypotensive activities of Minoxidil.Approved
MirtazapineBrofaromine may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Brofaromine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Brofaromine is combined with Moclobemide.Approved
MoexiprilBrofaromine may increase the hypotensive activities of Moexipril.Approved
MoxonidineBrofaromine may increase the hypotensive activities of Moxonidine.Approved
MuzolimineBrofaromine may increase the hypotensive activities of Muzolimine.Experimental
NadololBrofaromine may increase the hypotensive activities of Nadolol.Approved
NaftopidilBrofaromine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brofaromine.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Brofaromine.Approved, Investigational
NateglinideBrofaromine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololBrofaromine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Brofaromine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Brofaromine.Withdrawn
NicardipineBrofaromine may increase the hypotensive activities of Nicardipine.Approved
NicorandilBrofaromine may increase the hypotensive activities of Nicorandil.Approved
NiguldipineBrofaromine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBrofaromine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineBrofaromine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineBrofaromine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineBrofaromine may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideBrofaromine may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineBrofaromine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Brofaromine.Approved, Illicit
NortriptylineBrofaromine may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinBrofaromine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Olanzapine.Approved, Investigational
OlmesartanBrofaromine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Olodaterol.Approved
OmapatrilatBrofaromine may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolBrofaromine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Brofaromine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Orciprenaline.Approved
OxprenololBrofaromine may increase the hypotensive activities of Oxprenolol.Approved
PargylineBrofaromine may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Brofaromine.Approved, Investigational
PenbutololBrofaromine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineBrofaromine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brofaromine.Approved, Vet Approved
PentoliniumBrofaromine may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Brofaromine.Approved, Vet Approved, Withdrawn
PerindoprilBrofaromine may increase the hypotensive activities of Perindopril.Approved
PethidineBrofaromine may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Brofaromine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Brofaromine.Approved
PheniprazineBrofaromine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Brofaromine.Experimental
PhenoxybenzamineBrofaromine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineBrofaromine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Brofaromine.Approved, Illicit
PhentolamineBrofaromine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineBrofaromine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Brofaromine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Brofaromine.Investigational
PinacidilBrofaromine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololBrofaromine may increase the hypotensive activities of Pindolol.Approved
PioglitazoneBrofaromine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Brofaromine.Investigational
PirlindolePirlindole may increase the hypertensive activities of Brofaromine.Approved
PivhydrazineBrofaromine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenBrofaromine may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideBrofaromine may increase the hypotensive activities of Polythiazide.Approved
PramlintideBrofaromine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinBrofaromine may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Procaterol.Approved
PropranololBrofaromine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineBrofaromine may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Brofaromine.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Brofaromine.Approved
QuinaprilBrofaromine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineBrofaromine may increase the hypoglycemic activities of Quinine.Approved
RamiprilBrofaromine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Brofaromine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brofaromine.Approved
RemikirenBrofaromine may increase the hypotensive activities of Remikiren.Approved
RepaglinideBrofaromine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineBrofaromine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Reserpine.Approved
RilmenidineBrofaromine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatBrofaromine may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Brofaromine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Ritodrine.Approved
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Brofaromine.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Brofaromine.Approved, Investigational
RosiglitazoneBrofaromine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineBrofaromine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Salmeterol.Approved
SaprisartanBrofaromine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinBrofaromine may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Brofaromine.Approved, Investigational, Vet Approved
SelexipagBrofaromine may increase the hypotensive activities of Selexipag.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Brofaromine.Approved
SitagliptinBrofaromine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanBrofaromine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilBrofaromine may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brofaromine.Approved, Investigational
SulfadiazineBrofaromine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleBrofaromine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleBrofaromine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Brofaromine.Approved, Investigational
SunitinibBrofaromine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololBrofaromine may increase the hypotensive activities of Talinolol.Investigational
TelmisartanBrofaromine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilBrofaromine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Terbutaline.Approved
TerlipressinBrofaromine may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Brofaromine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Brofaromine.Approved
TetrahydropalmatineBrofaromine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineBrofaromine may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineBrofaromine may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Brofaromine.Approved
TiboloneBrofaromine may increase the hypotensive activities of Tibolone.Approved
TicrynafenBrofaromine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Brofaromine.Experimental
TimololBrofaromine may increase the hypotensive activities of Timolol.Approved
TolazamideBrofaromine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineBrofaromine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBrofaromine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brofaromine.Approved, Withdrawn
TolonidineBrofaromine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Brofaromine.Approved
TorasemideBrofaromine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Brofaromine.Approved, Investigational
TrandolaprilBrofaromine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Brofaromine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Brofaromine.Approved
TravoprostBrofaromine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Brofaromine is combined with Trazodone.Approved, Investigational
TreprostinilBrofaromine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideBrofaromine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinBrofaromine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanBrofaromine may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineBrofaromine may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneBrofaromine may increase the hypotensive activities of Unoprostone.Approved
UrapidilBrofaromine may increase the hypotensive activities of Urapidil.Investigational
ValsartanBrofaromine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Brofaromine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Brofaromine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Brofaromine.Approved
VincamineBrofaromine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBrofaromine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Brofaromine.Approved
XipamideBrofaromine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineBrofaromine may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Brofaromine.Withdrawn
ZofenoprilBrofaromine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Brofaromine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
KEGG Drug
D02560
ChemSpider
40549
BindingDB
50288969
ChEMBL
CHEMBL160347
Wikipedia
Brofaromine
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0321 mg/mLALOGPS
logP3.36ALOGPS
logP2.69ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area34.4 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity74.36 m3·mol-1ChemAxon
Polarizability29.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzofurans
Sub Class
Not Available
Direct Parent
Benzofurans
Alternative Parents
Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / Aryl bromides / Heteroaromatic compounds / Furans / Oxacyclic compounds / Dialkylamines / Azacyclic compounds
show 3 more
Substituents
Benzofuran / Anisole / Alkyl aryl ether / Aralkylamine / Aryl bromide / Aryl halide / Benzenoid / Piperidine / Heteroaromatic compound / Furan
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Lotufo-Neto F, Trivedi M, Thase ME: Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999 Mar;20(3):226-47. [PubMed:10063483]

Drug created on August 02, 2017 13:35 / Updated on September 01, 2017 12:37